Crossmark

A new era in headache treatment

Crossref DOI link: https://doi.org/10.1007/s10072-018-3337-y

Published Online: 2018-06-12

Published Print: 2018-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Vikelis, Michail

Spingos, Konstantinos C.

Rapoport, Alan M.
License Information

Text and Data Mining valid from 2018-06-01
More Information

Article History

First Online: 12 June 2018

Compliance with ethical standards

:

: M. Vikelis received investigator fees and/or advisory board member and/or consultancy and/or travel grants from Amgen, Allergan, Brain Therapeutics, Novartis, and Reckitt Beckinser. K Spingos received editorial fees and/or travel grants from Brain Therapeutics and Allergan. A Rapoport is on the speakers’ bureau for Amgen, Depomed, Promius division of Doctor Reddy’s, and TEVA. He is a consultant for Amgen, Autonomic Technologies, Depomed, Promius, Impax, Teva, and Zosano.